Advertisement

Pulsatile Delivery for Controlling Drug Release

Chapter
Part of the Advances in Delivery Science and Technology book series (ADST)

Abstract

The mechanisms and modes of drug action are such that systems ­providing constant and persistent plasma levels may not be optimally effective with some drugs and clinical conditions. At times, drug may need to be delivered at a specific time, for a certain period, to a specific location. “Delivery on demand” may even be optimal in response to the presence of a specific “biomarker-type” mediator. There is in consequence much interest in systems that can deliver drug from a unit in a time, location, or stimulus-driven mode. This chapter discusses the potential, possibilities, and limitations for pulsatile delivery so that therapy can meet the above requirements.

Keywords

Alginate Bead Pulse Release Nocturnal Asthma Rigid Barrier Capsule Body 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Khan MA, Sastry SV, Vaithiyalingam SR, Agarwal V, Nazzal S, Reddy IK (2000) Captopril gastrointestinal therapeutic system coated with cellulose acetate pseudolatex: evaluation of main effects of several formulation variables. Int J Pharm 193:147–156PubMedCrossRefGoogle Scholar
  2. 2.
    Lundberg JP, Sjöblom B (1999) Oral pharmaceutical pulsed release dosage form. WO/1999/032093, July 1999Google Scholar
  3. 3.
    Amidon GL, Leesman GD (1993) Pulsatile drug delivery system. US Patent 5,229,131 WO/1999/032093, July 1993Google Scholar
  4. 4.
    Mandal AS, Biswas N, Karim KM, Guha A, Chatterjee S, Behera M, Kuotsu K (2010) Drug delivery system based on chronobiology – a review. J Control Release 147:314–325PubMedCrossRefGoogle Scholar
  5. 5.
    Yano H, Hirayama F, Kamada M, Arima H, Uekama K (2002) Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Control Release 79:103–112PubMedCrossRefGoogle Scholar
  6. 6.
    Lemmer B (1989) Temporal aspects of the effects of cardiovascular active drugs in humans. In: Lemmer B (ed) Chronopharmacology: cellular and biochemical interactions. Marcel Dekker, New York, pp 525–541Google Scholar
  7. 7.
    Smolensky MH, Lemmer B, Reinberg AE (2007) Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Deliv Rev 59:852–882PubMedCrossRefGoogle Scholar
  8. 8.
    Lemmer B (2007) Chronopharmacology of cardiovascular medications. Biol Rhythm Res 38:247–258CrossRefGoogle Scholar
  9. 9.
    Brod M, Thomsen TL, Christensen T (2010) Evaluating the choice of pen versus syringe: implications for long-term diabetes management. Value Health 13:A529CrossRefGoogle Scholar
  10. 10.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (1999) An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 125:427–429PubMedCrossRefGoogle Scholar
  11. 11.
    Labrecque G, Reinberg AE (1989) Chronopharmacology of nonsteroid anti-inflammatory drugs. In: Lemmer B (ed) Chronopharmacology: cellular and biochemical interactions. Marcel Dekker, New York, pp 525–541Google Scholar
  12. 12.
    Gassler JP, Bisognano JD (2009) Commentary: revisiting the early morning blood pressure surge and myocardial ischemia. J Clin Hypertens 11:348–350CrossRefGoogle Scholar
  13. 13.
    Bogaty P, Waters DD (1989) Possible mechanisms accounting for the temporal distribution of anginal attacks. In: Lemmer B (ed) Chronopharmacology: cellular and biochemical interactions. Marcel Dekker, New York, pp 525–541Google Scholar
  14. 14.
    Jarret RJ (1989) Temporal aspects of blood glucose regulation: implications for diabetic patients. In: Lemmer B (ed) Chronopharmacology: cellular and biochemical interactions. Marcel Dekker, New York, pp 525–541Google Scholar
  15. 15.
    Sanders SW, Moore JG (1992) Gastrointestinal chronopharmacology – physiology, pharmacology and therapeutic implications. Pharmacol Ther 54:1–15PubMedCrossRefGoogle Scholar
  16. 16.
    Elliott WJ (2001) Timing treatment to the rhythm of disease – a short course in chronotherapeutics. Postgrad Med 110:119–122PubMedCrossRefGoogle Scholar
  17. 17.
    Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:377–421PubMedCrossRefGoogle Scholar
  18. 18.
    Kilgore D, Najm W (2010) Common respiratory diseases. Prim Care 37:297–324PubMedCrossRefGoogle Scholar
  19. 19.
    Ohdo S (2010) Chronotherapeutic strategy: rhythm monitoring, manipulation and disruption. Adv Drug Deliv Rev 62:859–875PubMedCrossRefGoogle Scholar
  20. 20.
    Reinberg AE (1989) Chronopharmacology of H1-Antihistamines. In: Lemmer B (ed) Chronopharmacology: cellular and biochemical interactions. Marcel Dekker, New York, pp 525–541Google Scholar
  21. 21.
    Sharma S, Pawar A (2006) Low density multiparticulate system for pulsatile release of meloxicam. Int J Pharm 313:150–158PubMedCrossRefGoogle Scholar
  22. 22.
    Badve SS, Sher P, Korde A, Pawar AP (2007) Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery. Eur J Pharm Biopharm 65:85–93PubMedCrossRefGoogle Scholar
  23. 23.
    Haus E (2007) Chronobiology in the endocrine system. Adv Drug Deliv Rev 59:985–1014PubMedCrossRefGoogle Scholar
  24. 24.
    Sajan J, Cinu TA, Chacko AJ, Litty J, Jaseeda T (2009) Chronotherapeutics and chronotherapeutic drug delivery systems. Trop J Pharm Res 8:467–475Google Scholar
  25. 25.
    Reinberg A, Pauchet F, Ruff F, Gervais A, Smolensky MH, Levi F, Gervais P, Chaouat D, Abella ML, Zidani R (1987) Comparison of once-daily evening versus morning sustained-release theophylline dosing for nocturnal asthma. Chronobiol Int 4:409–419PubMedCrossRefGoogle Scholar
  26. 26.
    Martin RJ, Banks-Schlegel S (1998) Chronobiology of asthma. Am J Respir Crit Care Med 158:1002–1007PubMedGoogle Scholar
  27. 27.
    Portaluppi F, Hermida RC (2007) Circadian rhythms in cardiac arrhythmias and opportunities for their chronotherapy. Adv Drug Deliv Rev 59:940–951PubMedCrossRefGoogle Scholar
  28. 28.
    Smith DHG (2001) Pharmacology of cardiovascular chronotherapeutic agents. Am J Hypertens 14:2965–3015CrossRefGoogle Scholar
  29. 29.
    Waldhausl W (1989) Circadian-rhythms of insulin needs and actions. Diabet Res Clin Pract 6:S17–S24CrossRefGoogle Scholar
  30. 30.
    Obaidat AA, Park K (1997) Characterization of protein release through glucose-sensitive hydrogel membranes. Biomaterials 18:801–806PubMedCrossRefGoogle Scholar
  31. 31.
    Zhang R, Tang M, Bowyer A, Eisenthal R, Hubble J (2006) Synthesis and characterization of a D-glucose sensitive hydrogel based on CM-dextran and concanavalin A. React Funct Polym 66:757–767CrossRefGoogle Scholar
  32. 32.
    Gandhi BR, Mundada AS, Gandhi PP (2011) Chronopharmaceutics: as a clinically relevant drug delivery system. Drug Deliv 18:1–18PubMedCrossRefGoogle Scholar
  33. 33.
    Youan B-BC (2004) Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? J Control Release 98:337–353PubMedCrossRefGoogle Scholar
  34. 34.
    Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN (2009) Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis – maintenance of healing and symptom relief. Aliment Pharmacol Ther 30:895–907PubMedCrossRefGoogle Scholar
  35. 35.
    Abel C, Desilets AR, Willett K (2010) Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. Ann Pharmacother 44:871–877PubMedCrossRefGoogle Scholar
  36. 36.
    Paolino D, Fresta M, Sinha P, Ferrari M (2006) Drug delivery systems. In: Webster JG (ed) Encyclopedia of medical devices and instrumentation, 2nd edn. Wiley, New York, pp 437–495Google Scholar
  37. 37.
    Goldbart R, Kost J (1999) Calcium responsive bioerodible drug delivery system. Pharm Res 16:1483–1486PubMedCrossRefGoogle Scholar
  38. 38.
    Li ZS, Zou DW, Ma XQ, Chen J, Shi XG, Gong YF, Man XH, Gao L, Zhao YF, Wang R, Yan XY, Dent J, Sung JJ, Wernersson B, Johansson S, Liu WB, He J (2010) Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 105:2570–2577PubMedCrossRefGoogle Scholar
  39. 39.
    Patel M, Shah T, Amin A (2007) Therapeutic opportunities in colon-specific drug-delivery systems. Crit Rev Ther Drug Carrier Syst 24:147–202PubMedGoogle Scholar
  40. 40.
    van Hogezand RA, Witte AMC, Veenendaal RA, Wagtmans MJ, Lamers C (2001) Proximal Crohn’s disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis 7:328–337PubMedCrossRefGoogle Scholar
  41. 41.
    Rutgeerts PJ (2001) Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther 15:1515–1525PubMedCrossRefGoogle Scholar
  42. 42.
    Zheng YQ, Qiu YH, Lu MYF, Hoffman D, Reiland TL (1999) Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. Int J Pharm 185:83–92PubMedCrossRefGoogle Scholar
  43. 43.
    Stockis A, Sargentini-Maier ML, Otoul C, Connor A, Wilding I, Wray H (2010) Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely ­activated capsules and gamma scintigraphy: open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. Clin Ther 32:1813–1821PubMedCrossRefGoogle Scholar
  44. 44.
    Brøndsted H, Kopecek J (1991) Hydrogels for site-specific oral-drug delivery – synthesis and characterization. Biomaterials 12:584–592PubMedCrossRefGoogle Scholar
  45. 45.
    Van den Mooter G, Samyn C, Kinget R (1994) The relation between swelling properties and enzymatic degradation of azo polymers designed for colon-specific drug-delivery. Pharm Res 11:1737–1741PubMedCrossRefGoogle Scholar
  46. 46.
    Gazzaniga A, Busetti C, Moro L, Sangalli ME, Giordano F (1995) Time-dependent oral delivery systems for colon targeting. Stp Pharma Sci 5:83–88Google Scholar
  47. 47.
    Gupta VK, Beckert TE, Price JC (2001) A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development. Int J Pharm 213:83–91PubMedCrossRefGoogle Scholar
  48. 48.
    Kao CC, Chen SC, Sheu MT (1997) Lag time method to delay drug release to various sites in the gastrointestinal tract. J Control Release 44:263–270CrossRefGoogle Scholar
  49. 49.
    Brondsted H, Hovgaard L, Simonsen L (1995) Dextran hydrogels for colon-specific drug-delivery. 4. Comparative release study of hydrocortisone and prednisolone sodium-phosphate. Stp Pharma Sci 5:65–69Google Scholar
  50. 50.
    Wakerly Z, Fell JT, Attwood D, Parkins D (1996) Pectin/ethylcellulose film coating formulations for colonic drug delivery. Pharm Res 13:1210–1212PubMedCrossRefGoogle Scholar
  51. 51.
    Adkin DA, Kenyon CJ, Lerner EI, Landau I, Strauss E, Caron D, Penhasi A, Rubinstein A, Wilding IR (1997) The use of scintigraphy to provide “proof of concept” for novel polysaccharide preparations designed for colonic drug delivery. Pharm Res 14:103–107PubMedCrossRefGoogle Scholar
  52. 52.
    Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C (2000) Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci 10:43–52PubMedCrossRefGoogle Scholar
  53. 53.
    Gliko-Kabir I, Yagen B, Baluom M, Rubinstein A (2000) Phosphated crosslinked guar for colon-specific drug delivery II. In vitro and in vivo evaluation in the rat. J Control Release 63:129–134PubMedCrossRefGoogle Scholar
  54. 54.
    Krishnaiah YSR, Satyanarayana S, Prasad YVR, Rao SN (1998) Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. J Control Release 55:245–252PubMedCrossRefGoogle Scholar
  55. 55.
    Macleod GS, Fell JT, Collett JH, Sharma HL, Smith AM (1999) Selective drug delivery to the colon using pectin: chitosan: hydroxypropyl methylcellulose film coated tablets. Int J Pharm 187:251–257PubMedCrossRefGoogle Scholar
  56. 56.
    Sinha VR, Kumria R (2001) Polysaccharides in colon-specific drug delivery. Int J Pharm 224:19–38PubMedCrossRefGoogle Scholar
  57. 57.
    Krogel I, Bodmeier R (1999) Evaluation of an enzyme-containing capsular shaped pulsatile drug delivery system. Pharm Res 16:1424–1429PubMedCrossRefGoogle Scholar
  58. 58.
    Gloster TM, Turkenburg JP, Potts JR, Henrissat B, Davies GJ (2008) Divergence of catalytic mechanism within a glycosidase family provides insight into evolution of carbohydrate metabolism by human gut flora. Chem Biol 15:1058–1067PubMedCrossRefGoogle Scholar
  59. 59.
    Chourasia MK, Jain SK (2003) Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 6:33–66PubMedGoogle Scholar
  60. 60.
    Iannuccelli V, Coppi G, Leo E, Fontana F, Bernabei MT (2000) PVP solid dispersions for the controlled release of furosemide from a floating multiple-unit system. Drug Dev Ind Pharm 26:595–603PubMedCrossRefGoogle Scholar
  61. 61.
    Joseph NJ, Lakshmi S, Jayakrishnan A (2002) A floating-type oral dosage form for piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in rabbits. J Control Release 79:71–79PubMedCrossRefGoogle Scholar
  62. 62.
    Chen J, Blevins WE, Park H, Park K (2000) Gastric retention properties of superporous hydrogel composites. J Control Release 64:39–51PubMedCrossRefGoogle Scholar
  63. 63.
    Lee BJ, Ryu SG, Cui JH (1999) Controlled release of dual drug-loaded hydroxypropyl methylcellulose matrix tablet using drug-containing polymeric coatings. Int J Pharm 188:71–80PubMedCrossRefGoogle Scholar
  64. 64.
    Lee BJ, Cui JH, Kim TW, Heo MY, Kim CK (1998) Biphasic release characteristics of dual drug-loaded alginate beads. Arch Pharm Res 21:645–650PubMedCrossRefGoogle Scholar
  65. 65.
    Durig T, Venkatesh GM, Fassihi R (1999) An investigation into the erosion behaviour of a high drug-load (85%) particulate system designed for an extended-release matrix tablet. Analysis of erosion kinetics in conjunction with variations in lubrication, porosity and compaction rate. J Pharm Pharmacol 51:1085–1092PubMedCrossRefGoogle Scholar
  66. 66.
    Krogel I, Bodmeier R (1999) Floating or pulsatile drug delivery systems based on coated effervescent cores. Int J Pharm 187:175–184PubMedCrossRefGoogle Scholar
  67. 67.
    Chen C-M (1995) Pulsatile particles drug delivery system. US Patent 5,472,708, Dec 1995Google Scholar
  68. 68.
    Chen C-M (1993) Multiparticulate pulsatile drug delivery system. US Patent 5,260,068, Nov 1993Google Scholar
  69. 69.
    Narisawa S, Fukui E, Yoshino H, Hirakawa Y, Noda K (1994) Porosity-controlled ethylcellulose film coating. 5. Mechanism of drug-release from beads coated with porous ethylcellulose film. Chem Pharm Bull 42:2131–2134Google Scholar
  70. 70.
    Ueda S, Hata T, Asakura S, Yamaguchi H, Kotani M, Ueda Y (1994) development of a novel drug-release system, time-controlled explosion system (TES). 1. Concept and design. J Drug Target 2:35–44PubMedCrossRefGoogle Scholar
  71. 71.
    Ueda S, Ibuki R, Kimura S, Murata S, Takahashi T, Tokunaga Y, Hata T (1994) Development of a novel drug-release system, time-controlled explosion system (Tes). 3. Relation between lag time and membrane thickness. Chem Pharm Bull 42:364–367Google Scholar
  72. 72.
    Ueda S, Yamaguchi H, Kotani M, Kimura S, Tokunaga Y, Kagayama A, Hata T (1994) Development of a novel drug-release system, time-controlled explosion system (Tes). 2. Design of multiparticulate Tes and in-vitro drug-release properties. Chem Pharm Bull 42:359–363Google Scholar
  73. 73.
    Schultz P, Kleinebudde P (1997) A new multiparticulate delayed release system. 1. Dissolution properties and release mechanism. J Control Release 47:181–189CrossRefGoogle Scholar
  74. 74.
    Schultz P, Tho I, Kleinebudde P (1997) A new multiparticulate delayed release system. 2. Coating formulation and properties of free films. J Control Release 47:191–199CrossRefGoogle Scholar
  75. 75.
    Kok P, Vonk P, Kossen NWF (2000) A particulate pulse-release system and mathematical description with the Maxwell-Stefan theory. J Control Release 66:293–306CrossRefGoogle Scholar
  76. 76.
    Magruder PR, Barclay B, Wong PSL, Theeuwes F (1989) Composition comprising a therapeutic agent and a modulating agent. US Patent 4,851,229, July 1989Google Scholar
  77. 77.
    Fujioka K, Sato S, Takada Y, Sasaki Y, Tamura N (1991) Sustained pulsewise release pharmaceutical preparation. US Patent 5,011,692, April 1991Google Scholar
  78. 78.
    Pozzi F, Furlani P, Gazzaniga A, Davis SS, Wilding IR (1994) The time clock system – a new oral dosage form for fast and complete release of drug after a predetermined lag time. J Control Release 31:99–108CrossRefGoogle Scholar
  79. 79.
    Jiang HL, Zhu KJ (2000) Pulsatile protein release from a laminated device comprising of polyanhydrides and pH-sensitive complexes. Int J Pharm 194:51–60PubMedCrossRefGoogle Scholar
  80. 80.
    Lin SY, Lin KH, Li MJ (2001) Micronized ethylcellulose used for designing a directly compressed time-controlled disintegration tablet. J Control Release 70:321–328PubMedCrossRefGoogle Scholar
  81. 81.
    Ghimire M, McInnes FJ, Watson DG, Mullen AB, Stevens HNE (2007) In-vitro/in-vivo correlation of pulsatile drug release from press-coated tablet formulations: a pharmacoscintigraphic study in the beagle dog. Eur J Pharm Biopharm 67:515–523PubMedCrossRefGoogle Scholar
  82. 82.
    Gohel MC, Sumitra GM (2002) Modulation of active pharmaceutical material release from a novel ‘tablet in capsule system’ containing an effervescent blend. J Control Release 79:157–164PubMedCrossRefGoogle Scholar
  83. 83.
    Kroegel I, Bodmeier R (1997) Development of floating or pulsatile DDS based on effervescent cores. Proc Int Symp Control Release Bioact Mater 24:273–274Google Scholar
  84. 84.
    Krogel I, Bodmeier R (1999) Floating or pulsatile drug delivery systems based on coated effervescent cores. Int J Pharm 187:175–184PubMedCrossRefGoogle Scholar
  85. 85.
    Stevens HNE, Wilson CG, Welling PG, Bakhshaee M, Binns JS, Perkins AC, Frier M, Blackshaw EP, Frame MW, Nichols DJ, Humphrey MJ, Wicks SR (2002) Evaluation of Pulsincap (TM) to provide regional delivery of dofetilide to the human GI tract. Int J Pharm 236:27–34PubMedCrossRefGoogle Scholar
  86.  86.
    Binns J, Stevens HNE, McEwen J, Pritchard G, Brewer FM, Clarke A, Johnson ES, McMillan I (1996) The tolerability of multiple oral doses of Pulsincap(TM) capsules in healthy volunteers. J Control Release 38:151–158CrossRefGoogle Scholar
  87.  87.
    Makino K, Idenuma R, Ohshima H (1996) A model for erosion kinetics of a hydrogel matrix. Colloids Surf B Biointerfaces 8:93–100CrossRefGoogle Scholar
  88.  88.
    Krogel I, Bodmeier R (1999) Development of a multifunctional matrix drug delivery system surrounded by an impermeable cylinder. J Control Release 61:43–50PubMedCrossRefGoogle Scholar
  89.  89.
    Wong PSL, Theeuwes F, Larsen SD, Dong LC (1995) Osmotic device for delayed delivery of agent. US Patent 5,443,459, Aug 1995Google Scholar
  90.  90.
    Jeong YI, Ohno T, Hu ZP, Yoshikawa Y, Shibata N, Nagata S, Takada K (2001) Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method. J Control Release 71:175–182PubMedCrossRefGoogle Scholar
  91.  91.
    Ishibashi T, Ikegami K, Kubo H, Kobayashi M, Mizobe M, Yoshino H (1999) Evaluation of colonic absorbability of drugs in dogs using a novel colon-targeted delivery capsule (CTDC). J Control Release 59:361–376PubMedCrossRefGoogle Scholar
  92.  92.
    Stevens HNE (2003) Pulsincap and hydrophilic sandwich (HS) capsules: innovative time-delayed oral drug delivery technologies. Drugs Pharm Sci 126:257–262Google Scholar
  93.  93.
    Yu LX, Lipka E, Crison JR, Amidon GL (1996) Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 19:359–376PubMedCrossRefGoogle Scholar
  94.  94.
    McNeill ME, Rashid A, Stevens HNE (1994) Dispensing device. British Technology Group, London, UKGoogle Scholar
  95.  95.
    Bar-Shalom D, Slot L, Lee WW, Wilson CG (2003) Development of the Egalet technology. Drugs Pharm Sci 126:263–271Google Scholar
  96.  96.
    Stevens HNE, Rashid A, Bakhshaee M (1995) Dispensing device. British Technology Group, London, UKGoogle Scholar
  97.  97.
    Ross AC, MacRae RJ, Walther M, Stevens HNE (2000) Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. J Pharm Pharmacol 52:903–909PubMedCrossRefGoogle Scholar
  98.  98.
    McConville JT, Hodges LA, Jones T, Band JP, O’Mahony B, Lindsay B, Ross AC, Florence AJ, Stanley AJ, Humphrey MJ, Wilson CG, Stevens HNE (2009) A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers. J Pharm Sci 98:4251–4263PubMedCrossRefGoogle Scholar
  99.  99.
    McConville JT, Ross AC, Chambers AR, Smith G, Florence AJ, Stevens HNE (2004) The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation. Eur J Pharm Biopharm 57:541–549PubMedCrossRefGoogle Scholar
  100. 100.
    McConville JT, Ross AC, Florence AJ, Stevens HNE (2005) Erosion characteristics of an erodible tablet incorporated in a time-delayed capsule device. Drug Dev Ind Pharm 1:77–87Google Scholar
  101. 101.
    Amidon GL, Leesman GD, Sherman LB (1995) Multi stage drug delivery system. US Patent 5,387,421, Feb 1995Google Scholar
  102. 102.
    Crison JR, Siersma PR, Amidon GL (1996) A novel programmable oral release technology for delivering drugs: human feasibility testing using gamma scintigraphy. Proc Int Symp Control Release Bioact Mater 23:51–52Google Scholar
  103. 103.
    Crison JR, Siersma PR, Taylor MD, Amidon GL (1995) Programmable oral release technology. PORT Systems: a novel dosage form for time and site specific oral drug delivery. Proc Int Symp Control Release Bioact Mater 22:278–279Google Scholar
  104. 104.
    Takaya T, Ikeda C, Imagawa N, Niwa K, Takada K (1995) Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs. J Pharm Pharmacol 47:474–478PubMedCrossRefGoogle Scholar
  105. 105.
    Shibata N, Ohno T, Shimokawa T, Hu ZP, Yoshikawa Y, Koga K, Murakami M, Takada K (2001) Application of pressure-controlled colon delivery capsule to oral administration of glycyrrhizin in dogs. J Pharm Pharmacol 53:441–447PubMedCrossRefGoogle Scholar

Copyright information

© Controlled Release Society 2011

Authors and Affiliations

  1. 1.College of PharmacyThe University of Texas at AustinAustinUSA

Personalised recommendations